evaluation and comparison of different quality control methods in radiochemical purity determination of new peptide kits 99mtc-edda-tricine-hynic-tyr3-octreotide and 99mtc-edda-tricine-hynic-tyr3-octreotate for imaging somatostatin receptor positive tumors [persian]
Authors
abstract
introduction: using labeled peptides enjoys high importance in nuclear medicine. somatostatin analogs labeled with different radionuclide are vastly investigated for diagnosis or treatment of somatostatin receptor positive tumors. labeling somatostatin analogs with 99mtc as alternative of 111in needs doing different quality control method for determination of labeling yield and complex stability for clinic applications. methods: for determining radiochemical purity, three different methods were compared and evaluated including hplc, tlc and sep-pak. results: all the three methods were suitable for determining of radiochemical purity in peptide kits, although using hplc was more effective rather than the others. conclusion: hplc was the best method for determination of radiochemical purity of the peptide kits. tlc or sep-pak method should only be employed if hplc is not available in nuclear medicine clinics, and after training and gaining sufficient operational experience. methods: in this research, a new monoclonal antibody against colon cancer cells was prepared and antigen concentration in different cells determined by a radioimmunoassay method using iodine (i-125) labeled protein g. results: 125i-labeled protein g percent binding to white blood cell, ht29, ls180 and mcf7 cell lines were 7.1%, 91.2%, 75.8% and 40.2%, respectively. conclusion: regarding importance of monoclonal antibody applications, it is necessary to find an efficient method for their evaluation in cancer therapy. in this method, a radioactive agent with no count restriction was used. also by this method, amount of the antigen can be easily quantified.
similar resources
Preparation, formulation and quality control of one step kit 99mTc- EDDA/HYNIC-Tyr3-Octreotide as a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [Persian]
The high expression of somatostatin receptors in many tumours, have made receptor scintigraphy with 111In-DTPA-Octreotide a widly used procedure in nuclear medicine. Despite its clinical success, some limitation and drawbacks of radiolabelling with 111In remain, especially those concerned with the cost, availability and physical decay properties of this radionuclide. 99mTc-EDDA/HYNIC-Tyr3...
full textpreparation, formulation and quality control of one step kit 99mtc- edda/hynic-tyr3-octreotide as a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [persian]
the high expression of somatostatin receptors in many tumours, have made receptor scintigraphy with 111in-dtpa-octreotide a widly used procedure in nuclear medicine. despite its clinical success, some limitation and drawbacks of radiolabelling with 111in remain, especially those concerned with the cost, availability and physical decay properties of this radionuclide. 99mtc-edda/hynic-tyr3-toc w...
full textSynthesis, labeling, formulation and quality control of 99mTc-Tricine-HYNIC-Tyr³-Octreotide, a peptide radiopharmaceutical for imaging Somatostatin receptor positive tumors [Persian]
Somatostatin analoges labeled with different radionuclides are able used for imaging and treatment of somatostatin receptor positive tumors. In this study Tyr³-Octreotide protected at lysine as an analoge of somatostatin was conjugated with bifunctional chelating agent 6-BOC-hydrazinopyridine-3-carboxylic acid (BOC-HYNIC) and after deprotecting of conjugate, purification was performed wit...
full textsynthesis, labeling, formulation and quality control of 99mtc-tricine-hynic-tyr³-octreotide, a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [persian]
somatostatin analoges labeled with different radionuclides are able used for imaging and treatment of somatostatin receptor positive tumors. in this study tyr³-octreotide protected at lysine as an analoge of somatostatin was conjugated with bifunctional chelating agent 6-boc-hydrazinopyridine-3-carboxylic acid (boc-hynic) and after deprotecting of conjugate, purification was performed with prep...
full textPatient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children
BACKGROUND Technetium-99m-hydrazinonicotinamide-Tyr3-octreotide (99mTc-HYNIC-TOC) is recognized as a promising radiopharmaceutical for diagnosing neuroendocrine tumors (NETs). However, 99mTc-HYNIC-TOC dosimetry has been investigated only for adults. As pediatric radionuclide therapies become increasingly common, similar dosimetric studies for children are urgently needed. The aim of this study ...
full textAn intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
UNLABELLED The aim of this study was to compare the imaging abilities of the recently developed somatostatin analog, (99m)Tc-hydrazinonicotinyl-Tyr(3)-octreotide ((99m)Tc-HYNIC-TOC [(99m)Tc-TOC]), with (111)In-diethylenediaminepentaacetic acid-D-Phe(1)-octreotide ((111)In-OCT [Octreoscan]) in patients undergoing routine somatostatin receptor (SSTR) scintigraphy. METHODS Forty-one patients (20...
full textMy Resources
Save resource for easier access later
Journal title:
iranian journal of nuclear medicinePublisher: tehran university of medical sciences
ISSN 1681-2824
volume 14
issue 2 2006
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023